Messenger RNA expression of human toll like receptors 3, 7 and 9 in Peripheral blood of patients with Hepatitis B infection
DOI:
https://doi.org/10.7439/ijbar.v8i3.3954Abstract
Despite the availability of effective vaccine and antiviral therapy, hepatitis B remains a serious public health problem worldwide. In spite of tremendous work done in the past, some questions pertaining to hepatitis B biology is yet to be understood. For instance the molecular mechanism whereby host fails to eliminate the virus leading to persistent infection is clearly not known. As many works have been directed towards understanding adaptive immune response, the area of innate immunity is poorly explored. The aim of the present study was to elucidate the role of toll-like receptors, an important component of innate immunity, in patients with hepatitis B infection. The mRNA expression of TLRs were studied in a total of 51 hepatitis B patients (45 chronic and 6 hepatocellular carcinoma) and 45 healthy individuals hailing from Arunachal Pradesh of northeastern part of India by quantitative PCR in LC 480 (Roche) system utilizing SYBR green and in house designed primers. Expression of TLR3, TLR7 and TLR9 was increased by 1.09 and 1.11 fold respectively with significant increase in TLR9 mRNA (p=0.017) in chronic and HCC patients compared to healthy control. No significant association was found with TLR9 expression and serum HBV DNA load (r=0.0033, p=0.98).Significant association of TLR9 in hepatitis B patients show that TLR9 does play a key role in persistent HBV infection and hepatoceelular carcinoma.Downloads
References
Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68
Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol 2014; 28:20:24: 7707
World Health Organization. 2015. Fact Sheet, Hepatitis B, last updated July 2015.
http://www.who.int/mediacentre/factsheets/fs204/en/
Liang TJ. Hepatitis B: The Virus and Disease. Hepatology; 2009; 49 Suppl5: S13
Zhang E, Lu M. Toll?like receptor (TLR) -mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol 2015; 204:11
Isogawa M, Robek MD, FuruichiY, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79:7269
Pei RJ, Chen XW, Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol 2014; 7: 20:33:11618-29
Centers for Disease Control and Prevention, Atlanta USA. Hepatits B, acute, 2012 case definition. Last updated May 06, 2015
Centers for Disease Control and Prevention, Atlanta USA. Hepatits B, Chronic, 2012 case definition. Last updated May 06, 2015
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols 2008; 3:1101-08
Xu N, Yao HP, Sun Z, Chen Z. Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacologica Sinica 2008; 29, 239-44
Zhou J, Huang Y, Tian D, Xu D, Chen M, Wu H.. Expression of toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads. J Huazhong. Univ Sci Technolog Med Sci 2009; 29:3:313
Xie Q, Shen HC, Jia NN, Wang H, Lin LY, An BY. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009; 11:4:515-23
Sajadi SMA, Mirzaei V, Hassanshahi G, Khorramdelazad H, Daredor HY, Hosseini SMH et al.Decreased Expressions of Toll-Like Receptor 9 and its Signaling Molecules in Chronic Hepatitis B Virus
Medhi S, Deka M, Deka P, Swargiary SS, Hazam RK, Sharma MP et al; 2011. Promoter region polymorphism & expression profile of toll like receptor3 (TLR3) gene in chronic hepatitis C virus (HCV) patients from India. Indian J Med Res 2011; 134:2: 200
Lyn-Cook BD, Xie C, Oates J, Treadwell E, Word B, Hammons G, Wiley K. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol Immunol 2014; 61:1:38-43
Funk TE, Kottilil S, Gilliam B, Talwani R. Tickling the TLR7 to cure viral hepatitis. J Transl Med 2014; 12:129
Bhardwaj N. TLR AGONISTS: Are They Good Adjuvants? Cancer J 201016;4:382
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
How to Cite
